Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Am J Surg. 2009 Mar;197(3):403-7. doi: 10.1016/j.amjsurg.2008.11.014.

The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival.

Author information

  • 1Department of Surgery and the Center on Outcomes Research and Education, NorthShore University Health System, Evanston, and Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ssener@northshore.org

Abstract

BACKGROUND:

The goal of this study was to compare the characteristics of breast cancers and survival rates in HRT users versus nonusers.

METHODS:

Data were analyzed for 1055 patients > or = 50 years of age who had definitive therapy for breast cancer from 1994 through 2002.

RESULTS:

There were 471 (45%) HRT users. The median age at diagnosis was 61.0 years for HRT users and 68.0 years for HRT nonusers (P < .001). HRT users more often had tumors that were <1 cm (P = .007), node negative (P = .033), and grade I (P = .016). HRT users had a decreased risk of death versus nonusers (hazard ratio = .438, 95% confidence limit = .263 to .729, P = .002).

CONCLUSIONS:

HRT users developed breast cancer at a younger age than nonusers; HRT use was associated with the development of biologically more favorable cancers than those that developed in nonusers; and overall and disease-free survival rates were higher in HRT users than nonusers.

Comment in

PMID:
19245923
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk